8. Huntington disease
197 clinical trials,   171 drugs   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02907294
(ClinicalTrials.gov)
March 20168/3/2016Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy VolunteersRandomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy VolunteersHuntington DiseaseDrug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: PlaceboPalobiofarma SLFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauTerminated18 Years45 YearsBoth8Phase 1Spain
2NCT02208934
(ClinicalTrials.gov)
September 20144/8/2014Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male VolunteersStudy To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male VolunteersHuntington's DiseaseDrug: PBF-999;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LCompleted18 Years45 YearsMale32Phase 1Spain